ClinicalTrials.Veeva

Menu

Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Major Depressive Disorder

Study type

Observational

Funder types

Other

Identifiers

NCT03031665
2016P000693

Details and patient eligibility

About

Using an innovative multi-modal imaging approach, this study investigates the role of the neurochemical gamma-aminobutyric acid (GABA), brain activity, as well as hormones in understanding sex differences in Major Depressive Disorder (MDD). Further, the investigators will link these markers to symptoms of depression.

Full description

The goals of this research are to investigate: (1) functional and neurochemical features associated with depression irrespective of clinical state; (2) moderating effects of hormones on stress circuitry in MDD; and (3) sex differences in symptoms. To this end, the study is enrolling adults with current depression and remitted depression, along with a control group of psychiatrically health adults. Participants will have an magnetic resonance imaging (MRI) exam involving multiple imaging techniques (functional, structural, spectroscopic) while performing computer-based tests. Additional questionnaires and tests will be done outside the scanner to assess current symptoms and hormone levels. The integration of laboratory-based measures of reward and stress sensitivity, with state-of-the-art imaging techniques and hormonal assessments promises to provide novel insights in the sex-dependent manifestation and pathophysiology of MDD.

Enrollment

251 patients

Sex

All

Ages

18 to 25 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for all participants.

  • Males and females aged 18 through 25
  • Capable of providing written informed consent, and fluent in English
  • Right-handed
  • Absence of any psychotropic medications for at least 2 weeks
  • Female subjects will be scheduled to participate during the follicular phase of their menstrual cycle

Inclusion Criteria for "Current MDD" group:

  • Meets inclusion criteria for all subjects, plus:
  • Meets diagnostic criteria for a current episode of Major Depressive Disorder (MDD), as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Inclusion Criteria for "Remitted MDD" group:

  • Meets inclusion criteria for all subjects, plus:
  • History of MDD as defined by DSM-5, but in remission for the past two months
  • Absence of anxiety disorder for the past two months

Exclusion Criteria for all participants:

  • History of psychiatric illnesses, other than depression or anxiety disorders among the Current MDD and Remitted MDD groups.
  • History of psychotic episodes, suicidal ideation, or of electroconvulsive therapy (ECT) treatment
  • Use of hormone replacement therapy, or of anabolic steroids.
  • Use of hormonal contraceptives is permitted for female subjects only if the subject has regular menses
  • Failure to meet any MRI safety requirements
  • Serious or unstable medical illness, or history of neurological disease or damage
  • History of use of cocaine, stimulants, or dopaminergic drugs
  • History of substance use disorder or alcohol use disorder (as these terms are defined by DSM-5); except depressed subjects may have a history of 'Mild' substance/alcohol use disorder only if it ended as least 12 months ago.

Trial design

251 participants in 3 patient groups

Current MDD
Description:
Subjects experiencing a current episode of Major Depressive Disorder.
Remitted MDD
Description:
Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
Control Subjects
Description:
Subjects who have no history of clinical depression or other psychological disorder.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems